Takahiro Iwasawa

Niigata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Clinical Significance of Transjugular Liver Biopsy in Liver Dysfunction During Immune Checkpoint Inhibitor Therapy.

Clinical Significance of Transjugular Liver Biopsy in Liver Dysfunction During Immune Checkpoint Inhibitor Therapy.

Journal: Cancer diagnosis & prognosis

Published: May 05, 2026

Clinical Characteristics and Technical Outcomes of Microballoon Catheter-assisted Partial Splenic Embolization.

Clinical Characteristics and Technical Outcomes of Microballoon Catheter-assisted Partial Splenic Embolization.

Journal: In vivo (Athens, Greece)

Published: April 15, 2026

Effect of Partial Splenic Embolization on Immune Environment and Hepatic Function in Cirrhosis Patients With Portal Hypertension.

Effect of Partial Splenic Embolization on Immune Environment and Hepatic Function in Cirrhosis Patients With Portal Hypertension.

Journal: In vivo (Athens, Greece)

Published: October 24, 2025

Efficacy of Durvalumab-Tremelimumab Treatment in Combination With Locoregional Therapy in Unresectable Hepatocellular Carcinoma: A Preliminary Study.

Efficacy of Durvalumab-Tremelimumab Treatment in Combination With Locoregional Therapy in Unresectable Hepatocellular Carcinoma: A Preliminary Study.

Journal: Cancer diagnosis & prognosis

Published: July 01, 2025

Angiotensin Receptor Neprilysin Inhibitors for Hypertension and Proteinuria Management During Atezolizumab/Bevacizumab Treatment for Hepatocellular Carcinoma.

Angiotensin Receptor Neprilysin Inhibitors for Hypertension and Proteinuria Management During Atezolizumab/Bevacizumab Treatment for Hepatocellular Carcinoma.

Journal: Cancer diagnosis & prognosis

Published: May 02, 2025

Transjugular Liver Biopsy for Histological Diagnosis of Refractory Ascites and Evaluation of Portal Hypertension.

Transjugular Liver Biopsy for Histological Diagnosis of Refractory Ascites and Evaluation of Portal Hypertension.

Journal: In vivo (Athens, Greece)

Published: February 12, 2025

Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.

Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.

Journal: In vivo (Athens, Greece)

Published: December 26, 2024

Effectiveness of Steerable Microcatheters During Transarterial Chemoembolization for Hepatocellular Carcinoma.

Effectiveness of Steerable Microcatheters During Transarterial Chemoembolization for Hepatocellular Carcinoma.

Journal: Cancer diagnosis & prognosis

Published: September 12, 2024

A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice.

A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice.

Journal: Inflammation and regeneration

Published: August 23, 2021

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.

Journal: Inflammation and regeneration

Published: June 15, 2021

Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma.

Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma.

Journal: Biochemical and biophysical research communications

Published: May 20, 2021

Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice.

Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice.

Journal: Regenerative therapy

Published: April 12, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026